Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Bremelanotide (Vyleesi) for hypoactive sexual desire disorder.

[No authors listed]

Med Lett Drugs Ther. 2019 Jul 29;61(1577):114-116. Review. No abstract available.

PMID:
31381550
2.

Expert opinion on existing and developing drugs to treat female sexual dysfunction.

Miller MK, Smith JR, Norman JJ, Clayton AH.

Expert Opin Emerg Drugs. 2018 Sep;23(3):223-230. doi: 10.1080/14728214.2018.1527901. Epub 2018 Oct 11. Review.

PMID:
30251897
3.

Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options.

Croft HA.

J Sex Med. 2017 Dec;14(12):1575-1584. doi: 10.1016/j.jsxm.2017.10.068. Review.

PMID:
29198512
4.

Sexual arousal: Sex matters.

Petherick A.

Nature. 2017 Oct 4;550(7674):S2-S3. doi: 10.1038/550S2a. No abstract available.

PMID:
28976951
5.

Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.

Clayton AH, Lucas J, DeRogatis LR, Jordan R.

Clin Ther. 2017 Mar;39(3):514-526.e14. doi: 10.1016/j.clinthera.2017.01.018. Epub 2017 Feb 9.

6.

Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.

White WB, Myers MG, Jordan R, Lucas J.

J Hypertens. 2017 Apr;35(4):761-768. doi: 10.1097/HJH.0000000000001221.

7.

Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.

Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ.

Womens Health (Lond). 2016 Jun;12(3):325-37. doi: 10.2217/whe-2016-0018. Epub 2016 May 16.

8.

Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.

√úckert S, Bannowsky A, Albrecht K, Kuczyk MA.

Expert Opin Investig Drugs. 2014 Nov;23(11):1477-83. doi: 10.1517/13543784.2014.934805. Epub 2014 Aug 6. Review.

PMID:
25096243
10.
11.

Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.

Nelson ME, Bryant SM, Aks SE.

Clin Toxicol (Phila). 2012 Dec;50(10):1169-73. doi: 10.3109/15563650.2012.740637. Epub 2012 Nov 5.

PMID:
23121206
12.

Central nervous system agents and erectile dysfunction.

Kumar R, Nehra A.

Urol Clin North Am. 2011 May;38(2):165-73. doi: 10.1016/j.ucl.2011.03.006. Review.

PMID:
21621083
13.

Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro.

Aughton KL, Hamilton-Smith K, Gupta J, Morton JS, Wayman CP, Jackson VM.

Br J Pharmacol. 2008 Sep;155(2):236-43. doi: 10.1038/bjp.2008.253. Epub 2008 Jun 30.

14.

Preclinical effects of melanocortins in male sexual dysfunction.

Shadiack AM, Althof S.

Int J Impot Res. 2008 Jul;20 Suppl 1:S11-6. doi: 10.1038/ijir.2008.17. Review.

PMID:
18552829
15.

Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.

Safarinejad MR, Hosseini SY.

J Urol. 2008 Mar;179(3):1066-71. doi: 10.1016/j.juro.2007.10.063. Epub 2008 Jan 18.

PMID:
18206919
17.

Bremelanotide: an overview of preclinical CNS effects on female sexual function.

Pfaus J, Giuliano F, Gelez H.

J Sex Med. 2007 Nov;4 Suppl 4:269-79.

PMID:
17958619
18.

Centrally acting mechanisms for the treatment of male sexual dysfunction.

Miner MM, Seftel AD.

Urol Clin North Am. 2007 Nov;34(4):483-96, v. Review.

PMID:
17983889
19.

Pharmaceutical aphrodisia.

Bridges TM.

Curr Top Med Chem. 2007;7(11):1152. No abstract available.

PMID:
17722370
20.

Melanocortins in the treatment of male and female sexual dysfunction.

Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ.

Curr Top Med Chem. 2007;7(11):1137-44. Review.

PMID:
17584134

Supplemental Content

Loading ...
Support Center